WFA
VIR icon

Wipfli Financial Advisors’s Vir Biotechnology VIR Stock Holding History

Wipfli Financial Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$25K Buy
+1,315
New +$33.4K ﹤0.01% 1478

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wipfli Financial Advisors's VIR Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Vir Biotechnology (VIR) in Q3 2022: 1,315 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #1478 among its holdings.

220 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • Wipfli Financial Advisors held 1,315 shares of Vir Biotechnology worth $25K as of Q3 2022.
  • Vir Biotechnology was a new Wipfli Financial Advisors position in Q3 2022.
  • Vir Biotechnology made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1478 holding.
  • 220 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.